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Receptor tyrosine kinases (RTKs) drive breast cancer progression, particularly in human
epidermal growth factor receptor 2 and basal tumors, the two worst prognosis subtypes.
Tumor cells recruit host stromal components, including immune cells, which strongly
inﬂuence disease progression.This has been studied in human breast cancer and translated
to murine models of breast cancer. Stromal immune components including cytotoxic T
lymphocytes (CTLs) and natural killer cells, destroy cancer cells through a process termed
immune surveillance. Unfortunately, clinically detectable tumors escape these immune
protective effects through their ability to limit the inﬁltration, activation, and/or survival
of CTLs in breast tumors. The immunosuppressed state of established tumors limits
the success rate of immune-based therapies, and possibly other therapeutic modalities
that depend on host immunity. Published studies demonstrate that RTKs facilitate breast
cancer progression, in part, by establishing immune suppression.This raises the intriguing
possibility that pharmacological RTK inhibitors may be exploited to sensitize breast cancer
patients to immune-based therapies.
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BREAST CANCER HETEROGENEITY
Major progress has been made since the recognition that breast
cancer is a heterogeneous disease, which is molecularly deﬁned by
ﬁve subtypes based on unique transcriptional proﬁles and expres-
sion of the estrogen and progesterone receptors (ER and PR) and
the human epidermal growth factor receptor 2 (HER2) receptor
tyrosine kinase (RTK). This includes normal, luminal A/B, HER2,
and basal/triple negative (ER−/PR−/HER2−) cancers (Perou et al.,
2000; van de Vijver et al., 2002; van ’t Veer et al., 2002). Within
these subtypes, HER2 and basal breast cancers represent 30–40%
of all newly diagnosed cases and are associated with the worst out-
come. The basal subtype is stratiﬁed into two groups: (1) basal
A tumors, which co-express basal (CK5/6, CK14) and luminal
(CK8/18) cytokeratins and (2) basal B or “claudin-low” tumors,
which lost their luminal characteristics (Neve et al., 2006), includ-
ing reduced expression of tight junctional proteins called claudins.
These tumors are enriched in genes associatedwith a stem cell phe-
notype and an epithelial to mesenchymal transition (Prat et al.,
2010; Taube et al., 2010).
Ampliﬁcation, overexpression or activation of RTK promotes
disease progression in HER2 and basal breast cancers. HER2
[also known as v-erb-b2 erythroblastic leukemia viral oncogene
homolog 2 (ErbB2)] ampliﬁcation is a deﬁning feature of the
HER2 subtype, correlating with poor outcome (Slamon et al.,
1989). Overexpression of ErbB2 in the mammary glands of trans-
genic mice leads to tumor development (Muller et al., 1988). The
Met RTK is a clinically relevant biomarker of poor outcome
basal breast cancers and drives the formation of mouse mam-
mary tumors with distinct histopathologies, a subset of which
resemble the basal subtype (Ponzo et al., 2009). Personalized ther-
apy targeting HER2 (trastuzumab), coupled with chemotherapy,
increases disease-free survival of early stage HER2+ breast can-
cer patients. Nonetheless, in the metastatic setting, these patients
are refractory to such combination therapies. While Met-targeted
therapies (Tivantinib) are in clinical trials in triple negative breast
cancer patients, chemotherapy remains the standard of care for
this subtype. This highlights the need to better understand fac-
tors that inﬂuence responsiveness to targeted therapies. Herein,
we discuss whether RTK therapies can locally re-activate anti-
tumor immunity and sensitize poor outcome breast cancers to
immunotherapy.
PARADOXICAL ROLE OF THE IMMUNE RESPONSE IN BREAST
CANCER
Breast cancer progression proceeds through well-deﬁned stages
starting from hyperplasia to ductal carcinoma in situ (DCIS),
transition to invasive ductal carcinoma (IDC) and development
of metastatic disease. Dynamic interactions between cancer and
immune cells inﬂuence each of these processes (Joyce and Pollard,
2009). Innate and adaptive immune cells polarize into numerous
lineages with contradicting roles during cancer progression. The
neoplastic process favors subtypes that exert a chronic inﬂamma-
tory and immunosuppressive state (de Visser et al., 2006).
CYTOTOXIC T LYMPHOCYTES
Cytotoxic T lymphocytes (CTLs) are CD8+ T cells that medi-
ate anti-tumor immunity. In concert with CD8, antigen-speciﬁc
T cell receptors bind to peptide-loaded major histocompatibility
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complex (MHC) class I molecules on the surface of tumor cells.
This activates CTLs to kill tumor cells by perforin-mediated per-
meabilization of the plasmamembrane and delivery of granzyme-
containing granules into the cytoplasm. Granzymes are serine
proteases that promote cell death through multiple mechanisms.
GranzymeA increases oxidative stress by decreasing themitochon-
drial membrane potential. In contrast, Granzyme B activates the
apoptotic machinery by cleaving numerous cellular targets. These
include: (1) direct cleavage and activation of effector caspases
(Caspase-3; Caspase-7) and (2) cleavage of Bid, a pro-apoptotic
Bcl2 family member, which translocates to and oligomerizes in the
outer mitochondrial membrane, which stimulates cytochrome c
release to promote apoptosome-mediated Caspase-9 activation.
Emerging evidence also suggests a novel pro-inﬂammatory role
for extracellular granzymes released from target cells (Cullen et al.,
2010). Along with natural killer (NK) cells, CTLs are primarily
responsible for immune surveillance (Schirrmacher, 2001). Ret-
rospective studies reveal a strong relationship between high CTL
recruitment and good outcome in breast cancer patients (Finak
et al., 2008; DeNardo et al., 2009).
MACROPHAGES/MYELOID-DERIVED SUPPRESSOR CELLS
WhileM1-polarizedmacrophages possess anti-tumorigenic prop-
erties, M2-type tumor-associated macrophages (TAMs) facilitate
tumorigenesis through their ability to secrete cytokines, growth
factors, and proteases that induce immunosuppression, angio-
genesis, and re-modeling of the extracellular matrix (Allavena
et al., 2008). Increased numbers of intra-tumoral macrophages
is indicative of poor outcome in breast cancer patients (Leek
et al., 2000; Tsutsui et al., 2005). Myeloid-derived suppressor cells
(MDSCs) are a heterogeneous population of progenitor cells
within the myeloid lineage. While these cells normally reside in
the bone marrow and differentiate prior to entering the blood-
stream, cancer cells induce the production of cytokines that
stimulate myelopoiesis and block their further differentiation
(Gabrilovich andNagaraj, 2009). Elevated circulatingMDSC levels
correlate with increasing grade and malignancy in breast cancer
patients (Diaz-Montero et al., 2009). These cells exhibit potent
immunosuppressive activity (Gabrilovich and Nagaraj, 2009).
HELPER T CELLS
CD4+ helper T (Th) cells differentiate into numerous sub lin-
eages that perform distinct biological functions (Zhu and Paul,
2008). Th1 cells elicit an anti-tumor immune response by secret-
ing high levels of interferon (IFN)γ and interleukin (IL)-2, which
induce M1 macrophage polarization and promote CTL prolifer-
ation/survival, respectively (de Visser et al., 2006). Regulatory T
cells (Tregs) establish immune suppression by inhibiting CTL/NK
cell function via diverse mechanisms. These include: (1) competi-
tive binding of IL-2 to the high afﬁnity IL-2 receptor (CD25); this
deprives effector T cells of IL-2, leading to apoptosis; (2) secre-
tion of immunosuppressive cytokines [IL-10 and transforming
growth factor beta (TGFβ)], which impairs antigen-activated CTL
clonal expansion; and (3) upregulation of cell surface inhibitory
molecules cytotoxic T lymphocyte associated protein 4 (CTLA-4)
that inhibit dendritic cell maturation (Vignali et al., 2008). Th2
cells induce B cell activation and differentiation, which stimulates
the production of inﬂammatory cytokines. Th2 cells also impair
CTL activation by (1) inhibiting Th1 differentiation, and (2)
secreting immunosuppressive cytokines such as IL-10 and TGFβ
(de Visser et al., 2006; Johansson et al., 2008). B and T cell inﬁl-
trates progressively increase during breast cancer progression, and
a high CD4/CD8 T cell ratio is associated with increased lymph
node positivity and poor outcome (DeNardo andCoussens, 2007).
This is recapitulated in murine breast cancer models where the
Th2 response induces M2-macrophage polarization and metasta-
sis (DeNardo et al., 2009). Th17 cells, which induce inﬂammation,
represent a new paradigm in cancer biology. While clinical studies
suggest that Th17 cell inﬁltration is associated with Th1-driven
anti-tumor immunity in breast cancer (Yang et al., 2012), others
demonstrate that Th17-mediated chronic inﬂammation potenti-
ates breast cancer progression in transgenic mouse models of the
disease (Novitskiy et al., 2011).
MECHANISMS TO ESTABLISH BREAST CANCER IMMUNE
SUPPRESSION
During the early stages of the neoplastic process, immune cells
recognize and destroy tumors through a process termed immune
surveillance (Ostrand-Rosenberg, 2008). Escaping tumor cells
proceed to an equilibrium phase whereby continuous interac-
tions between cancer and immune cells prevent tumor growth
(Schirrmacher, 2001). Both stages are controlled via the action
of CTL and NK cells. In the ﬁnal phase, cancer cells acquire the
ability to escape these immune-protective effects through a pro-
cess termed immune suppression and form clinically detectable
tumors (Dunn et al., 2002). Tumor cells employ multiple mecha-
nisms to impair CTL inﬁltration, activation or survival in order to
establish immunosuppression:
CHEMOKINE/CYTOKINE PRODUCTION
Cancer cells promote selective chemotaxis of polarized immune
cells that confer pro-tumorigenic properties. This is achieved via
the secretion of chemokines, which establish a chemical gra-
dient for immune cell types expressing their cognate receptor.
Numerous chemokines have been implicated in breast cancer
progression (Roussos et al., 2011). Breast cancer cells secrete
CCL17 and CCL22, which recruit CCR4-expressing Treg and Th2
cells (Faget et al., 2011). Elevated CCL22 expression is associ-
ated with increased Treg recruitment into primary DCIS and IDC
lesions, suggesting that Tregs may contribute to early breast can-
cer immunosuppression (Ohara et al., 2009). Breast cancer cells are
also rich sources of immunosuppressive cytokines, including IL-10
and TGFβ, which directly promote CTL anergy (Koli and Arteaga,
1996; Hamidullah et al., 2012). IL-10 is upregulated in ER/PR-
negative and HER2-positive breast tumors (Ohara et al., 2009).
In contrast, trafﬁcking of antigen-activated CXCR3-expressing
NK, CTL, and/or Th1 cells into tumor tissue is promoted
via the action of CXCL9 and CXCL10, two IFNγ-inducible
chemokines (Farber, 1997; Thapa et al., 2008). CXCL9 overexpres-
sion in breast cancer cells increases T cell inﬁltration, decreases
tumor growth and prolongs survival of immunocompetent but
not immunocompromised mice (Walser et al., 2007). Moreover,
CXCL9 overexpression in primary breast cancers is associated
with increased T cell inﬁltration and enhanced chemotherapy
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responsiveness (Specht et al., 2009; Denkert et al., 2010). This
suggests that CXCL9 promotes Th1/CTL-mediated anti-tumor
immunity.
ANTIGEN PROCESSING AND PRESENTATION
Major histocompatibility complex class I proteins, along with
components of the antigen processing and presentation (APP)
machinery are ubiquitously expressed in adult tissues. MHC class
I-restricted Ag presentation on the surface of breast cancer cells
contributes to immune surveillance through the activation of
CTLs, leading to tumor cell lysis. APP is a complex process.
Ubiquitinated proteins are cleaved by a multi-subunit complex
called the proteasome. Peptides are transported into the endo-
plasmic reticulum via the transporter associated with antigen
processing (TAP1, TAP2) heterodimerwhere they are processed by
ER aminopeptidase-associated with antigen processing (ERAP1,
ERAP2) proteins. Also in the ER, the MHC class I heavy human
leukocyte antigen (HLA) and light chains (β2-microglobulin)
assemble into a functional MHC class I complex. Finally, the pep-
tides are loaded onto MHC class I complexes and translocate to
the cell surface for presentation to CTLs (Seliger, 2008). Several
proteins involved in APP are deleted, mutated or downregulated
in breast cancer cells (Seliger, 2008). ErbB2 signaling reduces
expression levels of numerous components of the APP machin-
ery (Herrmann et al., 2004). Moreover, ErbB2-driven mammary
tumors display reduced surface MHC class I levels in transgenic
mice (Lollini et al., 1998). Finally, up to 50% of primary breast
cancers have reduced surface MHC class I expression, correlating
with increasing grade (Vitale et al., 1998; Gobbi et al., 2004).
DIMINISHED CYTOTOXIC T LYMPOCYTE EFFECTOR FUNCTION
The CD28 family of co-receptors are expressed on the surface
of T cells and transduce co-stimulatory or inhibitory signals fol-
lowing antigen activation. Programmed cell death 1 (PD1) is an
inhibitory member that is expressed on the surface of antigen-
activated CTLs. Upon binding to its cognate ligand programmed
cell death ligand 1 (PD-L1) on the surface of antigen presenting
cells, PD1 transduces a signal that reduces CTL proliferation and
cytolytic activity, eventually leading to CTL apoptosis (Flies et al.,
2011). PD-L1 is elevated on the surface of breast cancer cells, cor-
relating with a high mitotic index, increasing grade, and ER/PR
negativity (Ghebeh et al., 2006, 2007).
ANTI-TUMOR IMMUNITY IN POOR OUTCOME BREAST
CANCERS
An increasing body of evidence is emerging that Th1/CTL-
driven anti-tumor immunity plays a critical role in contributing
to enhanced patient outcome and therapeutic responsiveness in
breast cancer patients, particularly within the poor outcomeHER2
and basal subtypes.
PATIENT OUTCOME
Gene expression proﬁling has revolutionized how we study breast
cancer. The Park laboratory described the ﬁrst stromal-derived
prognostic predictor (SDPP) for breast cancer patients (Finak
et al., 2008). Subsets of genes within the SDPP include a Th1/CTL
signature that predicts reducedmortality in breast cancer patients,
independently of clinical variables such as grade, lymph node pos-
itivity, ER, and HER2 status (Finak et al., 2008).We independently
identiﬁed an immune signature, comprising B and T cell-speciﬁc
genes, which is elevated in mouse mammary tumors that are
impaired in ErbB2 signaling relative to wild-type tumors. This
signature functions as an independent prognostic marker of good
outcome in HER2 and basal breast cancer patients but not in the
luminal subtypes (Ursini-Siegel et al., 2010). Moreover, a Th2 sig-
nature is selectively enriched in poor outcome basal breast cancers
and an elevated Th1/Th2 ratio is highly predictive of good out-
come in HER2 and basal breast cancer patients (Kristensen et al.,
2012). These observations are consistent with studies demon-
strating that high intra-tumoral CTL inﬁltration is enriched in
ER−/PR−, and/or basal breast tumors and strongly correlates with
favorable prognosis in this subset (Baker et al., 2011; Mahmoud
et al., 2011; Liu et al., 2012). Paradoxically, increased CTL inﬁltra-
tion is associated with inferior outcome in low grade ER+ breast
cancer patients (Baker et al., 2011). Taken together, these observa-
tions provide strong clinical rationale to study how poor outcome
breast cancers impair Th1/CTL-driven immunitywithin theHER2
and basal subtypes.
THERAPEUTIC RESPONSIVENESS
Trastuzumab is a monoclonal antibody speciﬁc for ErbB2, which
when coupled with chemotherapy signiﬁcantly improves outcome
of early stage HER2+ breast cancer patients. The therapeutic
efﬁcacy of trastuzumab relies both on its ability to elicit anti-
tumor immunity by engaging FcR-mediated cytotoxicity and
by blocking ErbB2-driven signal transduction (Hudis, 2007).
Using pre-clinical mouse models, it has become clear that the
therapeutic effect of anti-ErbB2 monoclonal antibodies relies
on innate and adaptive immunity, including NK/CTL activity
and IFNγ responsiveness (Park et al., 2010; Stagg et al., 2011).
Indeed, trastuzumab sensitizes HER2-overexpressing tumors to
CTL-mediated lysis (Kono et al., 2004). Moreover, treatment of
ErbB2-driven mouse mammary tumors with ErbB2 neutralizing
antibodies together with v-akt murine thymoma viral oncogene
homolog 1 (AKT) inhibitors results in increased CTL inﬁltra-
tion and delayed tumor outgrowth (Wang et al., 2012). Finally,
HER2+ breast tumors treated with trastuzumab plus anthracy-
clines exhibit increased Th1/CTL-driven immunity relative to
chemotherapy alone (Ladoire et al., 2011). This suggests that
trastuzumab elicits anti-tumor immunity by attenuating breast
cancer immune suppression.
Emerging evidence suggests that chemotherapies function, in
part, by altering the immune microenvironment. It has been
demonstrated that subsets of HER2 and basal breast cancers are
highly sensitive to neo-adjuvant chemotherapy, displaying a four-
to sixfold increase in pathologic complete response (CR) rela-
tive to luminal tumors. Despite this fact, a large percentage of
patients within the HER2 and basal subtypes experience relapse
(Carey et al., 2007). Recent studies have shown that in ER negative
breast cancer, including theHER2 and basal subtypes, the presence
of tumor-inﬁltrating CTLs correlates with anthracycline respon-
siveness and prolonged patient survival compared to patients
without adjuvant chemotherapy (West et al., 2011). Finally, a
recent study further identiﬁed an immune signature (CD68high;
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CD4high; CD8low), which is indicative of high macrophage den-
sity and low CTL inﬁltration that predicts poor recurrence
free survival in node-positive breast cancer patients. Moreover,
macrophage inﬁltration is signiﬁcantly increased in breast tumors
from patients who underwent adjuvant chemotherapy compared
to women without any pre-operative intervention (DeNardo
et al., 2011). Macrophage inﬁltration is also enriched following
paclitaxel treatment and contributes to reduced chemosensitiv-
ity in the mouse mammary tumor virus/polyoma virus mid-
dle T (MMTV/PyvMT) breast cancer mouse model. Finally,
depletion of tumor associated macrophages increases CTL inﬁl-
tration and enhances anti-tumor immunity in MMTV/PyvMT
mice in response to paclitaxel (DeNardo et al., 2011). Take
together; this suggests that chemotherapies stimulate anti-tumor
immunity.
RECEPTOR TYROSINE KINASES INHIBIT ANTI-TUMOR
IMMUNITY
In addition to these clinical correlations, functional studies in
murine breast cancer models have demonstrated an important
role for RTK signaling in blocking anti-tumor immunity and
promoting disease progression. The laboratory of Dr. Brad
Nelson has engineered the ﬁrst immunological mouse model
for ErbB2-driven breast cancer. MMTV/ErbB2 transgenic mice
were generated using a modiﬁed version of ErbB2 that was
tagged with T cell epitopes from the model antigen ovalbumin
(OVA). A large panel of tumor cell lines [referred to as neu
ovalbumin peptide (NOP) lines] from spontaneous ErbB2/OVA-
expressing mammary tumors were established. When implanted
in host mice and challenged by adoptive transfer of OVA-speciﬁc
CTLs, NOP tumors show highly reproducible responses. Some
tumor lines demonstrate a CR, whereas others demonstrate a
partial response (PR) or progressive disease (PD; Wall et al.,
2007; Martin et al., 2010). This panel of cell lines provides a
unique and powerful system to deﬁne and manipulate the factors
that dictate the immunological sensitivity of mammary tumors
in vivo.
More recently, we established a unique transgenicmousemodel
of ErbB2-driven breast cancer in which mammary epithelial
expression of ErbB2/Neu is coupled to the Cre recombinase using
an intervening internal ribosome entry site (IRES) element neu-
ires-cre (NIC; Ursini-Siegel et al., 2008). MMTV/NIC mice were
employed to study the importance of the ShcA adaptor during
mammary tumorigenesis. ShcA transduces Grb2-dependent and
-independent signals downstream of RTKs to regulate prolifer-
ation, survival, angiogenesis, invasion, and metastasis (Northey
et al., 2008; Ursini-Siegel and Muller, 2008; Ursini-Siegel et al.,
2008). The majority of RTKs that are expressed in breast can-
cer cells, including ErbB2 and Met, couple to ShcA. Increased
ShcA signaling predicts nodal status and relapse in breast can-
cer patients (Davol et al., 2003; Frackelton et al., 2006). More-
over, high ShcA levels are enriched within the HER2 (ErbB2+)
and basal (ER−/PR−/ErbB2−) subtypes and associate with poor
outcome in breast cancer patients (Ursini-Siegel et al., 2010).
Using breast cancer mouse models that ablate ShcA expression
(NIC/ShcAﬂ/ﬂ), we deﬁned a causal role for ShcA in establish-
ing immune suppression. ShcA loss in the mammary epithe-
lium severely delays mammary tumor onset (Ursini-Siegel et al.,
2010). ShcA-deﬁcient pre-neoplastic lesions display enhanced
CTL-driven, anti-tumor immune responses, relative to their
wild-type counterparts. Emerging ShcA-deﬁcient tumors bypass
these anti-tumorigenic conditions by polarizing the immune
response to favor a Th2-driven immunity, which establishes
an immunosuppressive state (Ursini-Siegel et al., 2010). Thus,
RTKs, such as ErbB2, engage ShcA to establish immunosup-
pression and facilitate the emergence of clinically detectable
tumors.
CAN RTK INHIBITORS SENSITIZE TUMORS TO BREAST
CANCER IMMUNOTHERAPY?
The immune response is an attractive target for therapeutic
intervention in treating breast cancer. Several immune-based
therapies have been tested in clinical trials. These include: (1)
DNA, peptide and protein vaccines to tumor antigens such as
HER2 and MUC1, (2) autologous dendritic cell-based vaccines,
(3) cytokine therapies, including granulocyte macrophage-colony
stimulating factor (GM-CSF), as immune adjuvants, and (4)
compounds that block Treg function. Unfortunately, such trials
have met with limited success in treating breast cancer patients.
It is likely that local immunosuppression contributes to this
poor success rate (Wright, 2012). One approach to improving
the efﬁcacy of breast cancer immunotherapy is by manipulating
innate and adaptive immune cells to increase CTL inﬁltration
and/or cytotoxicity (DeNardo et al., 2011; Manjili and Payne,
2012). Published observations also suggest a critical role for
RTKs in establishing breast cancer immune suppression (Ursini-
Siegel et al., 2010). An increased Th1/CTL response is associated
with chemosensitivity and increased survival in HER2 and basal
breast cancer patients (Finak et al., 2008; DeNardo et al., 2009;
Ursini-Siegel et al., 2010; West et al., 2011). Finally, several RTK
inhibitors are approved (trastuzumab) or in clinical trials (Lap-
atinib, Erlotinib, Tivantinib) to treat breast cancer patients
within these poor outcome subtypes. This raises the intrigu-
ing possibility that pharmacological RTK inhibitors, alone or
in combination with chemotherapy, provide a therapeutic win-
dow to sensitize these poor outcome tumors to immune-based
therapies.
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